Hepatitis B Community
U.S. court invalidates patent on Bristol hepatitis B drug
About This Community:

This forum is an un-mediated, patient-to-patient forum for questions and support regarding Hepatitis B. Topics in this forum include but are not limited to, Causes, Diagnosis, Family and Relationships, Living With Hepatitis B, Research Updates, Treatment, Success Stories, Support, Symptoms.

Font Size:
A
A
A
Background:
Blank
Blank
Blank
Blank Blank

U.S. court invalidates patent on Bristol hepatitis B drug

A U.S. federal court has invalidated the U.S. patent on Bristol-Myers Squibb Co's Baraclude treatment for hepatitis B after a challenge from generic drugmaker Teva Pharmaceutical Industries Ltd, Bristol-Myers said on Tuesday.

"We are disappointed with the court's decision and believe it is incorrect," Bristol-Myers spokeswoman Laura Hortas said. She said the company is considering whether to appeal the ruling by the U.S. District Court in Delaware.  

Bristol-Myers had filed suit against Israeli drugmaker Teva in 2010 to block introduction of its generic form of Baraclude. Hortas said the drug's chemical patent lapses in February 2015, but declined to comment on whether U.S. regulators might allow Teva's generic onto the market before then.

Teva officials could not immediately be reached for comment.

ISI Group analyst Mark Schoenebaum said the U.S. Food and Drug Administration would have to approve Teva's marketing application before its generic could be introduced, and that it was unclear when the FDA might act.

Schoenebaum said Baraclude is expected to have U.S. sales this year of about $260 million. Even if the Teva generic arrives this year and hurts Baraclude's U.S. sales, he said Bristol-Myers will probably not need to lower its current full-year profit forecast.

Shares of Bristol-Myers were down 0.6 percent at $36.69 on the New York Stock Exchange on Tuesday morning. Teva shares were down 0.4 percent in Tel Aviv.

http://newsandinsight.thomsonreuters.com/Legal/News/2013/02_-_February/U_S__court_invalidates_patent_on_Bristol_hepatitis_B_drug/
6 Comments Post a Comment
Blank
Avatar_m_tn
This is a good wake up call for Bristol Myers to by or partner with Replicor.
Blank
Avatar_m_tn
so will baraclude be forbidden as a consequences of this invalidation ?
Blank
Avatar_m_tn
so ,

the price will reduce sooon .. every hbver can get the medicine all over the world ..
Blank
Avatar_m_tn
Baraclude generates $250+ million USD per year for BMS.  The drug is patented for 10 years so thats rougly $2.5 billion USD for BMS.

It would be in thier best interest to develop better drugs for the Hepatitis B market and have them available after the patent expires. Considering thier is a lot of potential to treat people, drug manufacturers should jump on the Hepatitis B market.
Blank
Avatar_m_tn
$250 million of USD is only USA market. Take into account rest of the world and there will be billions in just a month.
Blank
Avatar_m_tn
is that means the entecavir will become chaper and cheaper by this year 2013?
Blank
Post a Comment
To
Blank
Weight Tracker
Weight Tracker
Start Tracking Now
Hepatitis B Community Resources
RSS Expert Activity
233488_tn?1310696703
Blank
New Cannabis Article from NORTH Mag...
Jul 20 by John C Hagan III, MD, FACS, FAAOBlank
242532_tn?1269553979
Blank
3 Reasons Why You are Still Binge E...
Jul 14 by Roger Gould, M.D.Blank
242532_tn?1269553979
Blank
Emotional Eating: What Your Closet ...
Jul 09 by Roger Gould, M.D.Blank
Top Hepatitis Answerers
Avatar_m_tn
Blank
stef2011
Italy
Avatar_m_tn
Blank
StephenCastlecrag
Australia
Avatar_m_tn
Blank
Rome70
Moscow, Russia
Avatar_m_tn
Blank
andrey19
Russia
Avatar_m_tn
Blank
mer971
Avatar_m_tn
Blank
makeadifferencenow